Medicare AdvantageCoverageHigh impact
MA08.086e, Nusinersen (Spinraza®)
Independence Blue Cross·Neurology, Pediatrics, Pharmacy·Pharmacy
Effective date
Sep 14, 2026
We identified it
Sep 15, 2026
Summary
Policy MA08.086e for Nusinersen (Spinraza®) has been updated effective 09/14/2026. This is a Medicare Advantage policy addressing coverage, reimbursement position, and medical necessity criteria for this specialty pharmaceutical. The billing team must immediately obtain the full policy details to understand specific coverage requirements, prior authorization mandates, and any changes to reimbursement methodology.
Action Required
By 09/14/2026: Billing team must access the full policy text at the provided URL (https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=09&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#medicare-advantage-ma08-086e-nusinersen-spinraza) to extract specific HCPCS codes, prior authorization requirements, medical necessity criteria, and reimbursement rates. Update billing software with any new requirements for nusinersen claims. Pharmacy staff and prior authorization personnel must review medical necessity guidelines. Train all relevant staff on coverage changes before 09/14/2026. Failure to implement updates will result in claim denials for nusinersen administration.